Vasomune Therapeutics is a private biotechnology company focused on developing innovative therapies to treat vascular dysfunction, particularly through its lead drug candidate AV-001, which targets the Tie2 receptor to enhance vascular stability and counteract inflammation. The company aims to address critical conditions such as Acute Respiratory Distress Syndrome (ARDS) and has demonstrated efficacy in preclinical models. With a unique multifactorial approach, Vasomune differentiates itself from traditional therapies by promoting overall vascular health rather than targeting specific pathogens. The company is positioned to make significant impacts in the treatment of diseases associated with vascular leak, an area currently lacking effective therapies.
Something looks off?